Varicella-zoster virus IgG Antibodies ELISA Kit

Sample

Serum, plasma

Species Reactivity

Human

Detection Method

iELISA

Intended Use

This product is used for the in vitro qualitative detection of varicella-zoster virus IgG antibodies in human serum/plasma or whole blood samples.
It is suitable for the auxiliary diagnosis of varicella-zoster virus infection, the detection of varicella-zoster virus IgG antibody in vivo after varicella vaccination, and the detection of varicella-zoster virus IgG antibody in normal or susceptible people.

Contents of Kit

1. Pre-coated plate: 12T×8, inactivated purified varicella-zoster virus antigen
2. Mouse anti-human IgG monoclonal antibody enzyme label: 10ml × 1 bottle, HRP enzyme-labeled mouse anti-human IgG monoclonal antibody, containing stabilizer and biological preservatives
3. Concentrated washing solution (20×): 30ml×1 bottle, 20 times concentrated phosphate buffer, containing NaCl, Tween-20
4. Sample diluent: 50ml×1 bottle, sodium citrate buffer, stabilizer, etc.
5. Negative control substance: 0.5ml×1 bottle, inactivated human anti-varicella-zoster virus IgG negative serum, stabilizer
6. Positive control substance: 0.5ml×1 bottle, inactivated human anti-varicella-zoster virus IgG positive serum, stabilizer
7. Substrate A: 5.0ml×1 bottle, the main component is carbamide peroxide
8. Substrate B: 5.0ml×1 bottle, the main component is TMB
9. Stop solution: 5.0ml×1 bottle, 0.5M H₂SO₄ solution
10. Ziplock bag: 1 serving
11. Parafilm: 3 sheets

Storage

1. Store refrigerated at 2~8°C and away from light. Freezing is prohibited. The validity period is 12 months.
2. Unused pre-coated boards should be immediately put into a ziplock bag with desiccant and sealed, and the storage time should not exceed one week in an environment of 2~8°C.
3. Any unused reagents of other components should be capped immediately and stored in an environment of 2~8°C. The storage time should not exceed one week.
4. Please refer to the product label for the production date and expiration date of the product.

Precision

CV%＜15%

General Description

Varicella-zoster virus (VZV) is a double-stranded DNA virus of the genus Herpesvirus, subfamily Alphaherpesvirinae, and humans are its only host. Varicella-zoster enters the body through the mucous membranes of the nasopharynx and almost always causes disease in susceptible individuals. The incubation period is usually 14 to 16 (10 to 21) days. After chickenpox appears, the virus stays in the sensory nerve center and can cause shingles when reactivated later.
Varicella-zoster virus (VZV) is a highly contagious disease that occurs worldwide. Before vaccination, most people were infected by middle age. The epidemiology of varicella differs between temperate and tropical climates. Varicella-zoster virus (VZV) causes two different diseases, chickenpox and shingles. Immunocompetent individuals may experience prodromal symptoms of malaise and fever 1 or 2 days before the onset of rash, but these symptoms are often described as occurring simultaneously with the characteristic rash that is one of the main differences between chickenpox and smallpox. The rash appears in batches, with each batch progressing from spots to papules, vesicles, pustules, and eventually scabs, usually within 24 hours. A new batch of skin lesions occurred 5 to 6 days later, and skin lesions at different stages of healing could be seen during the course of the disease. The lesions are itchy and may scar. Chickenpox is more severe in pregnant women (especially in the third trimester of pregnancy) than in other adults, and the incidence of chickenpox in the fetus of pregnant women with chickenpox is significantly increased. Babies of mothers who contract chickenpox during pregnancy may develop congenital varicella syndrome. Chickenpox in immunocompromised individuals becomes more severe and becomes progressive chickenpox.
Nearly all immunocompetent people develop lifelong immunity to chickenpox after natural infection. Newborns passively acquire antibody protection from their immune mothers during their first few months. Unimmunized individuals can obtain temporary protection by injecting varicella-zoster immune globulin within 3 days of viral infection. The immunity acquired during chickenpox neither protects against possible VZV infection nor against subsequent reactivation of the herpes zoster virus. Although antibody testing can be conveniently used to indicate an immune response to previous infection or vaccination, the absence of VZV antibodies does not mean that the individual is susceptible because the corresponding cell-mediated immunity may still be intact. In addition, approximately 20% of people aged 55 to 65 years have no detectable cell-mediated VZV immunity despite having antibodies. Herpes zoster is closely associated with reduced levels of VZV-specific T cells, and herpes zoster reactivates specific T cell responses. The immunity generated by the chickenpox vaccine lasts 10 to 20 years. Chickenpox vaccination in childhood can provide 70% to 90% immune protection, and more than 95% of cases can prevent severe chickenpox 7 to 10 years after vaccination.
Currently, the main methods for detecting varicella-zoster virus-specific IgG antibodies include: fluorescent membrane antigen antibody assay (FAMA), latex agglutination (LA), enzyme-linked immunosorbent assay (ELISA), etc.